Caroline J. Atkinson

Caroline J. Atkinson

Auto-generated profile, based on publicly available information

Caroline J. Atkinson

Children's Cancer Institute at Minderoo Children's Comprehensive Cancer Centre

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 December 2015 in Prion
Verified
Journal Article
Open access
CACaroline J. Atkinson
Caroline J. Atkinson
KZKai Zhang
Kai Zhang
AMAlan L. Munn
Alan L. Munn
AWAdrian Wiegmans
Adrian Wiegmans
MWMing Wei
Ming Wei
Prions are infectious proteins and over the past few decades, some prions have become renowned for their causative role in several neurodegenerative diseases in animals and humans. Since their discovery, the mechanisms and mode of transmission and molecular structure of prions have begun to be established. There is, however, still much to be elucidated about prion diseases, including the development of potential therapeutic strategies for treatment. The significance of prion disease is discussed here, including the categories of human and animal prion diseases, disease transmission, disease progression and the development of symptoms and potential future strategies for treatment. Furthermore, the structure and function of the normal cellular prion protein (PrPC) and its importance in not only in prion disease development, but also in diseases such as cancer and Alzheimer's disease will also be discussed.

26 November 2018 in Molecular Oncology
Verified
Journal Article
Open access
PDF file
CACaroline J. Atkinson
Caroline J. Atkinson
FKFutoshi Kawamata
Futoshi Kawamata
CLCheng Liu
Cheng Liu
SHSunyoung Ham
Sunyoung Ham
BGBalázs Győrffy
Balázs Győrffy
AWAdrian P. Wiegmans
Adrian P. Wiegmans
Epidermal growth factor receptor (EGFR) supports colorectal cancer progression via oncogenic signaling. Anti‐EGFR therapy is being investigated as a clinical option for colorectal cancer, and an observed interaction between EGFR and Prion protein has been detected in neuronal cells. We hypothesized that PrPC expression levels may regulate EGFR signaling and that detailed understanding of this signaling pathway may enable identification of resistance mechanisms and new actionable targets in colorectal cancer. We performed molecular pathway analysis following knockdown of PrPC or inhibition of EGFR signaling via gefitinib to identify changes in expression of key signaling proteins that determine cellular sensitivity or resistance to cisplatin. Expression of these proteins was examined in matched primary and metastatic patient samples and was correlated for resistance to therapy and progression of disease. Utilizing three colorectal cancer cell lines, we observed a correlation between high expression of PrPC and resistance to cisplatin. Investigation of molecular signaling in a resistant cell line revealed that PrPC contributed to signaling via colocalization with EGFR, which could be overcome by targeting p38 mitogen‐activated protein kinases (p38 MAPK). We revealed that the level of Krüppel‐like factor 5 (KLF5), a target downstream of p38 MAPK, was predictive for cell line and patient response to platinum agents. Further, high KLF5 expression was observed in BRAF‐mutant colorectal cancer. Our study indicates that the EGFR to KLF5 pathway is predictive of patient progression on platinum‐based therapy.

21 March 2019 in JCI Insight
Verified
Journal Article
Closed access
PDF file
AWAdrian P. Wiegmans
Adrian P. Wiegmans
JSJodi Saunus
Jodi Saunus
SHSunyoung Ham
Sunyoung Ham
RLRichard Lobb
Richard Lobb
JKJamie Kutasovic
Jamie Kutasovic
Andreas MöllerAndreas Möller
Andreas Möller
Anthracyclines are among the most effective chemotherapeutics ever developed, but they produce grueling side effects and serious adverse events, and resistance often develops over time. We found that these compounds can be sequestered by secreted cellular prion protein (PrP C ), which blocks their cytotoxic activity. This effect was dose dependent using either cell line–conditioned medium or human serum as a source of PrP C . Genetic depletion of PrP C or inhibition of binding via chelation of ionic copper prevented the interaction and restored cytotoxic activity. This was more pronounced for doxorubicin than its epimer, epirubicin. Investigating the relevance to breast cancer management, we found that the levels of PRNP transcript in pretreatment tumor biopsies stratified relapse-free survival after neoadjuvant treatment with anthracyclines, particularly among doxorubicin-treated patients with residual disease at surgery. These data suggest that local sequestration could mediate treatment resistance. Consistent with this, tumor cell expression of PrP C protein correlated with poorer response to doxorubicin but not epirubicin in an independent cohort analyzed by IHC, particularly soluble isoforms released into the extracellular environment by shedding. These findings have important potential clinical implications for frontline regimen decision making. We suggest there is warranted utility for prognostic PrP C / PRNP assays to guide chemosensitization strategies that exploit an understanding of PrP C -anthracycline-copper ion complexes.

27 January 2020 in Cancer and Metastasis Reviews
Verified
Journal Article
Closed access
PDF file
AKAlvin Kamili
Alvin Kamili
CACaroline Atkinson
Caroline Atkinson
TTToby Trahair
Toby Trahair
JFJamie I. Fletcher
Jamie I. Fletcher

10 September 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
AKAlvin Kamili
Alvin Kamili
BHBrandon A Hearn
Brandon A Hearn
ITIsabella Temelkoska
Isabella Temelkoska
JSJoan Solomon
Joan Solomon
MWMadeleine S Wheatley
Madeleine S Wheatley
JFJamie I Fletcher
Jamie I Fletcher
Purpose : Treatment for children with high-risk neuroblastoma relies on conventional chemotherapy and anti-GD2 immunotherapy. However, 5-year survival is only 50%, with high rates of late effects. Targeted therapy combinations are a major priority for these patients. The BCL2 inhibitor venetoclax, in combination with cyclophosphamide/topotecan, has clinical activity in relapsed and refractory neuroblastoma. We sought more effective and safer venetoclax combinations through systematic preclinical testing. Experimental design : Synergistic combinations were identified by high-throughput screening using patient-derived xenograft (PDX) models and confirmed in vivo . The leading combination (venetoclax-alisertib) was compared to combination chemotherapy in a clinical trial-like study using 22 PDX models, in scheduling experiments designed to reduce short-term toxicity, and in combination with anti-GD2 immunotherapy. BCL2 and Bim-BCL2 complex protein levels were assessed as predictors of sensitivity. Results : In vitro synergy with venetoclax was observed for standard-of-care chemotherapies and targeted agents, including DNA topoisomerase, microtubule, HDAC and Aurora kinase A (AURKA) inhibitors. Venetoclax-alisertib was particularly effective in vivo . In an n=1 study, venetoclax-alisertib induced objective response in all models. Activity was most striking in models of MYCN -amplified disease (n=12), doubling median survival time compared to cyclophosphamide/topotecan, and outperforming venetoclax-cyclophosphamide-topotecan. Efficacy was maintained with discontinuous schedules, minimizing hematological toxicity without substantially compromising activity. PDX-engrafted animals treated with venetoclax-alisertib and anti-GD2 immunotherapy survived tumor-free long-term. BCL2 expression and BCL2-Bim complex levels were of limited value for predicting response. Conclusion : Our findings support advancement of BCL2-AURKA inhibition to clinical trial for neuroblastoma with or without anti-GD2 immunotherapy, particularly in patients with MYCN amplified disease.